HK1251260A1 - Bcl-2家族的異二聚體特異性抗體及其用途 - Google Patents
Bcl-2家族的異二聚體特異性抗體及其用途Info
- Publication number
- HK1251260A1 HK1251260A1 HK18110611.8A HK18110611A HK1251260A1 HK 1251260 A1 HK1251260 A1 HK 1251260A1 HK 18110611 A HK18110611 A HK 18110611A HK 1251260 A1 HK1251260 A1 HK 1251260A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- heterodimers
- bcl
- family
- antibodies specific
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5120608P | 2008-05-07 | 2008-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1251260A1 true HK1251260A1 (zh) | 2019-01-25 |
Family
ID=41264999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18110611.8A HK1251260A1 (zh) | 2008-05-07 | 2018-08-17 | Bcl-2家族的異二聚體特異性抗體及其用途 |
Country Status (4)
Country | Link |
---|---|
US (4) | US8168755B2 (zh) |
EP (2) | EP3284828A1 (zh) |
HK (1) | HK1251260A1 (zh) |
WO (1) | WO2009137664A1 (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012122370A2 (en) | 2011-03-08 | 2012-09-13 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
WO2013021384A1 (en) | 2011-08-11 | 2013-02-14 | Yeda Research And Development Co. Ltd | Compositions and methods for modulating apoptosis |
EP2847592A4 (en) | 2012-05-10 | 2016-05-04 | Eutropics Pharmaceuticals Inc | SURROGATE FUNCTIONAL DIAGNOSTIC TEST FOR CANCER |
WO2013192423A2 (en) | 2012-06-20 | 2013-12-27 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
US20160038503A1 (en) | 2012-11-21 | 2016-02-11 | David Richard | Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives |
US10732182B2 (en) | 2013-08-01 | 2020-08-04 | Eutropics Pharmaceuticals, Inc. | Method for predicting cancer sensitivity |
EP3063302B1 (en) | 2013-10-30 | 2019-12-04 | Eutropics Pharmaceuticals, Inc. | Methods for determining chemosensitivity and chemotoxicity |
US20160018414A1 (en) * | 2014-07-21 | 2016-01-21 | The Florida International University Board Of Trustees | SAB as a Biomarker for Degenerative Diseases and Therapeutic Sensitivity in Cancers |
KR20170126867A (ko) | 2015-01-12 | 2017-11-20 | 유트로픽스 파마슈티컬스, 인크. | 암 치료를 안내하기 위한 컨텍스트 의존성 진단 검사 |
WO2016154380A1 (en) * | 2015-03-24 | 2016-09-29 | Eutropics Pharmaceuticals, Inc. | Surrogate functional biomarker for solid tumor cancer |
AU2016252609B2 (en) | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
TR201911032T4 (tr) | 2015-05-18 | 2019-08-21 | Tolero Pharmaceuticals Inc | Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları. |
RU2759963C2 (ru) | 2015-08-03 | 2021-11-19 | Сумитомо Даиниппон Фарма Онколоджи, Инк. | Комбинированные терапии для лечения рака |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018119000A1 (en) | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
CA3089018A1 (en) * | 2018-01-18 | 2019-07-25 | Eutropics Pharmaceuticals, Inc. | Methods for predicting cancer drug responsiveness |
CN113490499A (zh) | 2018-12-04 | 2021-10-08 | 大日本住友制药肿瘤公司 | 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物 |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5622852A (en) * | 1994-10-31 | 1997-04-22 | Washington University | Bcl-x/Bcl-2 associated cell death regulator |
US5981201A (en) * | 1997-01-08 | 1999-11-09 | Beth Israel Deaconess Medical Center | Methods of detection and treatment of breast cancer |
US7064193B1 (en) * | 1997-09-17 | 2006-06-20 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules |
US7026456B1 (en) * | 1998-01-23 | 2006-04-11 | Hoffman-La Roche, Inc. | Antibodies against human IL-12 |
JP2002515267A (ja) | 1998-05-18 | 2002-05-28 | アポトーシス テクノロジー・インコーポレーテッド | 抗アポトーシス遺伝子及び遺伝子産物に関する化合物、スクリーニング方法並びに用途 |
US20020177692A1 (en) * | 2001-04-16 | 2002-11-28 | Myriad Genetics, Incorporated | BCL-XL-interacting protein and use thereof |
US7432304B2 (en) * | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
US7678893B2 (en) | 2002-12-26 | 2010-03-16 | Zakrytoe Aktsionernoe Obschestvo “Evrogen” | Fluorescent proteins from Copepoda species and methods for using same |
AU2004225439A1 (en) * | 2003-04-01 | 2004-10-14 | Monogram Biosciences, Inc. | Intracellular complexes as biomarkers |
US8323987B2 (en) * | 2004-02-17 | 2012-12-04 | The University Of North Carolina At Chapel Hill | Modulation of epidermal growth factor heterodimer activity |
EP2947160B1 (en) * | 2004-04-09 | 2017-07-12 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
-
2009
- 2009-05-07 WO PCT/US2009/043129 patent/WO2009137664A1/en active Application Filing
- 2009-05-07 EP EP17179402.7A patent/EP3284828A1/en not_active Withdrawn
- 2009-05-07 US US12/437,127 patent/US8168755B2/en active Active
- 2009-05-07 EP EP09743650A patent/EP2304047A4/en not_active Withdrawn
-
2012
- 2012-03-23 US US13/428,889 patent/US20120225794A1/en not_active Abandoned
-
2014
- 2014-04-30 US US14/266,424 patent/US20140234867A1/en not_active Abandoned
-
2017
- 2017-08-15 US US15/677,795 patent/US20180208672A1/en not_active Abandoned
-
2018
- 2018-08-17 HK HK18110611.8A patent/HK1251260A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20120225794A1 (en) | 2012-09-06 |
EP2304047A4 (en) | 2012-12-26 |
US8168755B2 (en) | 2012-05-01 |
US20180208672A1 (en) | 2018-07-26 |
EP3284828A1 (en) | 2018-02-21 |
WO2009137664A1 (en) | 2009-11-12 |
US20140234867A1 (en) | 2014-08-21 |
EP2304047A1 (en) | 2011-04-06 |
US20090280510A1 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251260A1 (zh) | Bcl-2家族的異二聚體特異性抗體及其用途 | |
HK1256622A1 (zh) | Il-6的抗體和其用途 | |
IL271270A (en) | Antibodies to 6-il and their use | |
PT2246427T (pt) | Anticorpos capazes de se ligar especificamente a oligómeros beta amilóides e a sua utilização | |
IL232276A0 (en) | Antibodies to 6-il and their uses | |
EP2427479A4 (en) | ANTIBODIES AND METHODS OF USE THEREOF | |
EP2373691A4 (en) | ANTI-FXI ANTIBODIES AND METHOD FOR THEIR USE | |
EP2504031A4 (en) | ANTI-IL-6 ANTIBODIES AND THEIR USE | |
ZA201102550B (en) | Antibodies that bind to il-18 and methods of purifying the same | |
IL218763A (en) | Anti-gcc antibody molecules, pharmaceutical compositions and methods of use | |
IL211623A0 (en) | Anti-notch2 antibodies and methods of use | |
IL215795A0 (en) | Anti-il-17f antibodies and methods of use thereof | |
PT2185719E (pt) | Anticorpos anti-rantes e processos para a sua utilização | |
IL215291A0 (en) | NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF | |
HK1178917A1 (zh) | 抗體及其用途 | |
EP2246430A4 (en) | ANTI-ADAM-15 ANTIBODIES AND THEIR USE |